Today, we announced the expansion of our ADC pipeline — and our collaboration with Synaffix — to develop two novel bispecific candidates. SOT112 and SOT113 are our first investigational bispecific ADCs for #cancer treatment. Read more in today’s release: sotio.com//news-publicat…

🧪Potential ADCs in GI cancers ESMO - Eur. Oncology Gastrointestinal Oncology ✅Claudin 18.2, Claudin 6, c-MET, CEACAM5, Mesothelin, Guanylyl cyclase C, EGFR, FGFR2, SLC44A4, 5T4, P-cadherin, HER3 👉doi.org/10.1016/j.esmo… OncoAlert #cancer #oncology #MedX

We look forward to presenting preclinical data for our potentially differentiated HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. EO-1022 leverages advanced site-specific

At the upcoming AACR Annual Meeting in Chicago, we’ll be presenting preclinical data on SOT106 and SOT109, our two most advanced #ADC programs to treat solid tumors. Full presentation details are in our press release: sotio.com/news-publicati… #AACR25 #Biotechnology

AACR 2025 Poster 2： Title: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors Session Start: 4/28/2025 2:00:00 PM Session End: 4/28/2025 5:00:00 PM Location: Poster Section 24

Odisha Teacher Result Out Today: Score: 50 marks Category- GC Status: Rejected Score: 13 marks Category- ST Status: Accepted This is how we are hiring teachers in schools. Now imagine the future of students who will learn from them !!

sacituzumab govitecan (SG) vs sacituzumab tirumotecan (Sac-TMT) = antibody ≈ DAR (7.6 vs 7.4) ≠ conjugation chemistry (maleimide vs pyrimidine) ≈ linker (except conjugation part) = carbonate cleavable group ≠ payload structure and properties (SN-38 vs KL610023)

In academia, ‘visibility factors’ play a HUGE role. A PhD is just a bare minimum. In the past, I applied for faculty positions & was interviewed across the US (and a bit in Europe). I naively assumed that a great research proposal were key to getting a faculty position. But

Honored to be speaking at AACR25 educational session on next generation ADCs - Raffaele Colombo Raffaele Colombo AACR Elisabeth de Vries Josh Drago Paolo Tarantino AACR President Lillian L. Siu oncodaily.com/blog/raffaele-… #Cancer #Medicine #Health #AACR25 #MedX #MedNews #MedEd #CancerResearch #Oncology

If you attended the Chemistry to the Clinic session on Expanding the Therapeutic Window of Antibody Drug Conjugates in Cancer, be sure to give this recent article by session speaker Christian Hackenberger a read. doi.org/10.1158/1535-7… #AACR25

#AACR25, Excited to share that our abstract (TumeyLab) received the AACR-John Kincade Scholar-in-Training Award for early-career scientists at #AACR2025! Incredible ADC talks so far — looking forward to the amazing poster sessions starting today! #AACR #ADCs #CancerResearch

Online now. Simultaneous publication with an #AACR25 poster: The #FirstDisclosure of PF-08046032: A Novel, Investigational CD25-Directed Antibody-drug Conjugate Optimized for Selective Depletion of Regulatory T cells in Advanced Malignant Tumors: doi.org/10.1158/1535-7… AACR

Binghamton University, Binghamton University School of Pharmacy, TumeyLab, Researching the researchers: A look into the school of pharmacy’s post-doctoral program binghamton.edu/news/story/546…

The #FDA has granted fast track designation to ADRX-0706, a Nectin-4-targeted ADC, for the treatment of patients with advanced cervical cancer. #gyncsm hubs.li/Q03lRcQ30

"Scientists are the working-class noble community, and they are doing everything for the community." Chemistry laureate David MacMillan speaks on the role of scientists and their contributions to our society.

#OnlineFirst: Anti-HER2, High-DAR Antibody Fragment Drug Conjugates (FDC) with a Glucuronide-based MMAE Linker-Payload Demonstrates Superior Efficacy over IgG-based ADCs. doi.org/10.1158/1535-7… #HER2 #FirstDisclosure

Preclinical development of DB-1419 published on Clinical Cancer Research! DB-1419 is a bispecific ADC (bsADC) 🎯 = B7H3 x PDL1 💊 = P1003 (TOPO1i) #️⃣ = DAR8 aacrjournals.org/clincancerres/… A mini thread 🧵

🧬 I'm taking part in an NSF I-Corps program to explore market needs for immune-modulating therapies. Looking to speak with 10–15 folks involved in treating autoimmune diseases or developing related drugs. If you're up for a quick 10–15 min chat, DM me or drop a comment. Thanks!